BRIDGEWATER, N.J., March 7, 2018 /PRNewswire/ -- Amneal
Pharmaceuticals LLC and Impax Laboratories, Inc. (NASDAQ: IPXL)
today announced that they will jointly present at the Barclays
Global Healthcare Conference at the Loews Miami Beach Hotel in
Miami, Florida on Tuesday, March 13, 2018 at 2:35 p.m. ET.
Paul Bisaro, President and CEO of
Impax, Bryan Reasons, Senior Vice
President and Chief Financial Officer of Impax, and Robert Stewart, President of Amneal
Pharmaceuticals will participate in a fireside chat. To access a
live webcast of the presentation, visit Impax's Investor Relations
Web site at https://investors.impaxlabs.com/Investor-Relations. The
webcast can also be accessed at the following URL:
https://cc.talkpoint.com/barc002/031318a_as/?entity=104_04B7MF1
An archived version will be available approximately one hour
after the live presentation and can be accessed at the same
locations for 90 days.
About Amneal
Amneal Pharmaceuticals LLC, a
privately-held company headquartered in Bridgewater, New Jersey, is one of the largest
and fastest growing generic pharmaceutical manufacturers in
the United States. Founded in
2002, Amneal now has more than 5,000 employees in its operations in
North America, Asia, and Europe, working together to bring
high-quality, affordable medicines to patients worldwide. Amneal
has significantly expanded its portfolio of generic products to
include complex dosage forms in a broad range of therapeutic areas.
For more information, visit www.amneal.com.
About Impax
Impax Laboratories, Inc. is a specialty
pharmaceutical company applying its formulation expertise and drug
delivery technology to the development of controlled-release and
specialty generics in addition to the development of central
nervous system disorder branded products. Impax markets its generic
products through its Impax Generics division and markets its
branded products through the Impax Specialty Pharma division.
Additionally, where strategically appropriate, Impax develops
marketing partnerships to fully leverage its technology platform
and pursues partnership opportunities that offer alternative dosage
form technologies, such as injectables, nasal sprays, inhalers,
patches, creams, and ointments. For more information, please visit
Impax's web site at: www.impaxlabs.com.
Additional Information and Where to Find It
This
communication does not constitute an offer to sell or the
solicitation of an offer to buy any securities or a solicitation of
any vote or approval. This communication may be deemed to be
solicitation material in respect of the proposed transaction
between Impax Laboratories, Inc. ("Impax") and Amneal
Pharmaceuticals LLC ("Amneal") pursuant to the Business Combination
Agreement dated as of October 17,
2017 by and among Impax, Amneal, Atlas Holdings, Inc.
("Holdco"), and K2 Merger Sub Corporation, as amended by Amendment
No. 1, dated November 21, 2017, and
Amendment No. 2, dated December 16,
2017. In connection with the proposed transaction, Holdco
filed a registration statement on Form S- 4, containing a proxy
statement/prospectus, with the Securities and Exchange Commission
("SEC") on November 21, 2017,
Amendment No. 1 to the registration statement filed on December 29, 2017, Amendment No. 2 to the
registration statement filed on January 23,
2018, Amendment No. 3 to the registration statement filed on
February 1, 2018 and Amendment No. 4
to the registration statement filed on February 6, 2018, which was declared effective by
the SEC on February 9, 2018. Impax
has filed a definitive proxy statement on Schedule 14A with the SEC
on February 12, 2018, and the
definitive proxy statement and a form of proxy have been mailed to
the shareholders of Impax on or about February 13, 2018. This communication is not a
substitute for the registration statement, definitive proxy
statement/prospectus or any other documents that Impax or Holdco
may file or have filed with the SEC, or will send or have sent to
stockholders in connection with the proposed business
combination.
INVESTORS AND SECURITY HOLDERS OF IMPAX ARE URGED TO READ ALL
RELEVANT DOCUMENTS FILED WITH THE SEC, INCLUDING THE PROXY
Investors and security holders will be able to obtain copies of the
registration statement, including the proxy statement/prospectus
and other documents filed with the SEC (when available) free of
charge at the SEC's website, http://www.sec.gov. Copies of the
documents filed with the SEC by Impax or Holdco will be available
free of charge on Impax's internet website at
http://www.impaxlabs.com or by contacting Mark Donohue, Investor Relations and Corporate
Communications at (215) 558-4526.
Participants in Solicitation
Impax, Amneal, Holdco
and their respective directors and executive officers may be deemed
to be participants in the solicitation of proxies from Impax's
stockholders in respect of the proposed transaction. Information
about the directors and executive officers of Impax is set forth in
its proxy statement for its 2017 annual meeting of stockholders,
which was filed with the SEC on April 5,
2017, and in its Annual Report on Form 10-K for the year
ended December 31, 2016. Other
information regarding the participants in the proxy solicitations
and a description of their direct and indirect interests, by
security holdings or otherwise, are contained in the proxy
statement/prospectus regarding the proposed transaction and other
relevant materials that have been or will be filed with the SEC
when they become available. You may obtain free copies of these
documents as described in the preceding paragraph.
This communication is not intended to and shall not constitute an
offer to sell or the solicitation of an offer to sell or the
solicitation of an offer to buy any securities or a solicitation of
any vote of approval, nor shall there be any sale of securities in
any jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such jurisdiction. No offering of securities
shall be made except by means of a prospectus meeting the
requirements of Section 10 of the Securities Act of 1933, as
amended.
Forward-Looking Statements
This communication includes
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Forward-looking statements are based on our
beliefs and assumptions. These forward-looking statements are
identified by terms and phrases such as: anticipate, believe,
intend, estimate, expect, continue, should, could, may, plan,
project, predict, will, target, potential, forecast, and the
negative thereof and similar expressions. Forward-looking
statements by their nature address matters that are, to different
degrees, uncertain, such as statements about the potential timing
or consummation of the proposed transaction or the anticipated
benefits thereof, including, without limitation, future financial
and operating results. Impax cautions readers that these and other
forward-looking statements are not guarantees of future results and
are subject to risks, uncertainties and assumptions that could
cause actual results to differ materially from those expressed in
any forward-looking statements. Important risk factors that could
cause actual results to differ materially from those indicated in
any forward-looking statement include, but are not limited to: (i)
the ability to obtain shareholder and regulatory approvals, or the
possibility that they may delay the transaction or that such
regulatory approval may result in the imposition of conditions that
could cause the parties to abandon the transaction, (ii) the risk
that a condition to effecting the transaction may not be satisfied;
(iii) the ability of Impax and Amneal to integrate their businesses
successfully and to achieve anticipated synergies, (iv) the
possibility that other anticipated benefits of the proposed
transaction will not be realized, including without limitation,
anticipated revenues, expenses, earnings and other financial
results, and growth and expansion of the new combined company's
operations, and the anticipated tax treatment, (v) potential
litigation relating to the proposed transaction that could be
instituted against Impax, Amneal or their respective directors,
(vi) possible disruptions from the proposed transaction that could
harm Impax's and/or Amneal's business, including current plans and
operations, (vii) the ability of Impax or Amneal to retain, attract
and hire key personnel, (viii) potential adverse reactions or
changes to relationships with clients, employees, suppliers or
other parties resulting from the announcement or completion of the
transaction, (ix) potential business uncertainty, including changes
to existing business relationships, during the pendency of the
business combination that could affect Impax's or Amneal's
financial performance, (x) certain restrictions during the pendency
of the transaction that may impact Impax's or Amneal's ability to
pursue certain business opportunities or strategic transactions,
(xi) continued availability of capital and financing and rating
agency actions, (xii) legislative, regulatory and economic
developments; (xiii) unpredictability and severity of catastrophic
events, including, but not limited to, acts of terrorism or
outbreak of war or hostilities, as well as management's response to
any of the aforementioned factors; and (xiv) such other factors as
are set forth in Impax's periodic public filings with the SEC,
including but not limited to those described under the headings
"Risk Factors" and "Cautionary Statement Regarding Forward-Looking
Information" in Impax's Form 10-K for the fiscal year ended
December 31, 2016, in the Form S-4
filed by Holdco, in the definitive proxy statement on Schedule 14A
filed by Impax and in Impax's other filings made with the SEC from
time to time, which are available via the SEC's website at
www.sec.gov. While the list of factors presented here is, and the
list of factors to be presented in the proxy statement are,
considered representative, no such list should be considered to be
a complete statement of all potential risks and uncertainties.
Unlisted factors may present significant additional obstacles to
the realization of forward looking statements. Consequences of
material differences in results as compared with those anticipated
in the forward-looking statements could include, among other
things, business disruption, operational problems, financial loss,
legal liability to third parties and similar risks, any of which
could have a material adverse effect on Impax's or Amneal's
consolidated financial condition, results of operations, credit
rating or liquidity. In light of these risks, uncertainties and
assumptions, the events described in the forward-looking statements
might not occur or might occur to a different extent or at a
different time than Impax has described. All such factors are
difficult to predict and beyond our control. All forward-looking
statements included in this document are based upon information
available to Impax on the date hereof, and unless legally required,
Impax disclaims and does not undertake any obligation to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
CONTACTS:
Amneal
Apurva Saraf
(631) 742 7674
Impax
Mark Donohue
(215) 558-4526
View original
content:http://www.prnewswire.com/news-releases/amneal-pharmaceuticals-and-impax-laboratories-to-present-at-the-barclays-global-healthcare-conference-300609786.html
SOURCE Impax Laboratories, Inc.